Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
The Oncologist · 02.02.2024 · 29 (2) · 142-150
DOI: 10.1093/oncolo/oyad231 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Oncologist, online erschienen am 17.08.2023. Verfasst von Toni K Choueiri und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Med…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck Sharp & Dohme LLC.
Abstract (Originalsprache)
Background
In patients with renal cell carcinoma (RCC) enrolled in the phase III KEYNOTE-564 trial (NCT03142334), disease-free survival (DFS) following nephrectomy was prolonged with use of adjuvant pembrolizumab therapy versus placebo. Patient-reported outcomes (PROs) provide an important measure of health-related quality of life (HRQoL) and can complement efficacy and safety results. Patients and Methods In KEYNOTE-564, 994 patients were randomly assigned to receive pembrolizumab 200 mg (n = 496) or placebo (n = 498) intravenously every 3 weeks for ≤17 cycles. Patients who received ≥1 dose of treatment and completed ≥1 HRQoL assessment were included in this analysis. HRQoL end points were assessed using the EORTC QLQ-C30, FKSI-DRS, and EQ VAS. Prespecified and exploratory PRO end points were mean change from baseline in EORTC QLQ-C30 GHS/QoL score, EORTC QLQ-C30 physical function subscale score, and FKSI-DRS score.
Results
No clinically meaningful difference in least squares mean scores for pembrolizumab versus placebo were observed at week 52 for EORTC QLQ-C30 GHS/QoL (–2.5; 95% CI –5.2 to 0.1), EORTC QLQ-C30 physical functioning (–0.87; 95% CI –2.7 to 1.0), and FKSI-DRS (–0.7; 95% CI –1.2 to –0.1). Most PRO scores remained stable or improved for the EORTC QLQ-C30 GHS/QoL (pembrolizumab, 54.3%; placebo, 67.5%), EORTC QLQ-C30 physical functioning (pembrolizumab, 64.7%; placebo, 68.8%), and FKSI-DRS (pembrolizumab, 58.2%; placebo, 66.3%).
Conclusions
Adjuvant treatment with pembrolizumab did not result in deterioration of HRQoL. These findings together with the safety and efficacy findings support adjuvant pembrolizumab treatment following nephrectomy. Trial Registration Clinicaltrials.gov Identifier: NCT03142334
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
- Department of Medical Oncology, Poznan University of Medical Sciences, Poznan, Poland.
- Department of Hematology and Oncology, Sungkyunkwan University Samsung Medical Center, Seoul, South Korea.
- Department of Medical Oncology, The Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, UK.
- Department of Medical Oncology, Edinburgh Cancer Centre, NHS Lothian, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
- Department of Medical Oncology, Fakultní Nemocnice Ostrava, Ostrava, Czech Republic.
ORCID-Profile: Toni K Choueiri
Förderung
- Merck Sharp & Dohme LLC
Zitieren
APA
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Symeonides, S., Hajek, J., Ferguson, T., Chang, Y. H., Lee, J. L., Haas, N., Sawrycki, P., Sarwar, N., Gross-Goupil, M., Thiery-Vuillemin, A., Mahave, M., Kimura, G., Perini, R. F., Saretsky, T. L., Bhattacharya, R., …, & Powles, T. (2024). Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma. The Oncologist, 29(2), 142-150. https://doi.org/10.1093/oncolo/oyad231
Vancouver
Choueiri TK, Tomczak P, Park SH, Venugopal B, Symeonides S, Hajek J, et al. Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma. The Oncologist. 2024;29(2):142-150. doi:10.1093/oncolo/oyad231
BibTeX
@article{Choueiri2024,
author = {Choueiri, Toni K and Tomczak, Piotr and Park, Se Hoon and Venugopal, Balaji and Symeonides, Stefan and Hajek, Jaroslav and Ferguson, Thomas and Chang, Yen-Hwa and Lee, Jae Lyun and Haas, Naomi and Sawrycki, Piotr and Sarwar, Naveed and Gross-Goupil, Marine and Thiery-Vuillemin, Antoine and Mahave, Mauricio and Kimura, Go and Perini, Rodolfo F and Saretsky, Todd L and Bhattacharya, Rituparna and Xu, Lei and Powles, Thomas},
title = {Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {2},
pages = {142--150},
doi = {10.1093/oncolo/oyad231}
}
EUVIMED